Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.
The CEO of Gaithersburg’s miRecule Inc. was a former oncology researcher with the National Cancer Institute who spun his business out of the NIH in 2016. The company has since secured millions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback